Skip to main content
Erschienen in: Inflammation 3/2016

20.02.2016 | EDITORIAL

Nobiletin: A Citrus Isolate to Make Sepsis Less Sour

verfasst von: Patrick M. Honore, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Herbert D. Spapen

Erschienen in: Inflammation | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

Septic shock remains a major concern in critically ill patients. Morbidity, as reflected by cardiovascular instability and sequential organ failure, is high and mortality ranges from 20 to 50 % [1]. Treatment options are scarce and mainly cause-oriented and symptomatic. Substantial efforts to control the coordinate but sometimes profuse and potentially lethal sepsis-induced immuno-inflammatory response remained unsuccessful. Indeed, large studies investigating numerous “magic bullets” interfering with sepsis-related immune-inflammatory or coagulation processes failed to show efficacy on relevant outcome parameters [24]. Also, the theoretical benefit of blood purification by restoring immune homeostasis through indiscriminate removal of inflammatory mediators could not be confirmed [5]. …
Literatur
2.
Zurück zum Zitat Cohen, J., J.L. Vincent, N.K. Adhikari, F.R. Machado, D.C. Angus, T. Calandra, et al. 2015. Sepsis: a roadmap for future research. Lancet Infectious Diseases 5: 581–614.CrossRef Cohen, J., J.L. Vincent, N.K. Adhikari, F.R. Machado, D.C. Angus, T. Calandra, et al. 2015. Sepsis: a roadmap for future research. Lancet Infectious Diseases 5: 581–614.CrossRef
3.
Zurück zum Zitat Panacek, E.A., J.C. Marshall, T.E. Albertson, D.H. Johnson, S. Johnson, R.D. MacArthur, et al. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 232: 2173–2182.CrossRef Panacek, E.A., J.C. Marshall, T.E. Albertson, D.H. Johnson, S. Johnson, R.D. MacArthur, et al. 2004. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Critical Care Medicine 232: 2173–2182.CrossRef
4.
Zurück zum Zitat Ranieri, V.M., B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, S. Finfer, et al. 2012. Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine 366: 2055–2064.CrossRefPubMed Ranieri, V.M., B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, S. Finfer, et al. 2012. Drotrecogin alfa (activated) in adults with septic shock. The New England Journal of Medicine 366: 2055–2064.CrossRefPubMed
5.
Zurück zum Zitat Joannes-Boyau, O., P.M. Honoré, P. Perez, S.M. Bagshaw, H. Grand, J.L. Canivet, et al. 2013. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Medicine 39: 1535–1546.CrossRefPubMed Joannes-Boyau, O., P.M. Honoré, P. Perez, S.M. Bagshaw, H. Grand, J.L. Canivet, et al. 2013. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): A multicentre randomized controlled trial. Intensive Care Medicine 39: 1535–1546.CrossRefPubMed
6.
Zurück zum Zitat Li F, Wang X, Niu X, Zhang H, He Z, Wang Y et al. 2016. Protective effects of nobiletin against endotoxic shock in mice through inhibiting TNF-α, IL-6, HMGB1 and regulating NF-κB pathway. Inflammation Li F, Wang X, Niu X, Zhang H, He Z, Wang Y et al. 2016. Protective effects of nobiletin against endotoxic shock in mice through inhibiting TNF-α, IL-6, HMGB1 and regulating NF-κB pathway. Inflammation
7.
Zurück zum Zitat Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.CrossRefPubMed Wang, H., O. Bloom, M. Zhang, J.M. Vishnubhakat, M. Ombrellino, J. Che, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.CrossRefPubMed
8.
Zurück zum Zitat Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Molecular Medicine 21(Suppl 1): S6–S12.CrossRefPubMedPubMedCentral Yang, H., H. Wang, S.S. Chavan, and U. Andersson. 2015. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Molecular Medicine 21(Suppl 1): S6–S12.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bianchi, M.E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology 81: 1–5.CrossRefPubMed Bianchi, M.E. 2007. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology 81: 1–5.CrossRefPubMed
10.
Zurück zum Zitat Rouhiainen, A., S. Tumova, L. Valmu, N. Kalkkinen, and H. Rauvala. 2007. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). Journal of Leukocyte Biology 81: 49–58.CrossRefPubMed Rouhiainen, A., S. Tumova, L. Valmu, N. Kalkkinen, and H. Rauvala. 2007. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). Journal of Leukocyte Biology 81: 49–58.CrossRefPubMed
11.
Zurück zum Zitat Lee, S.A., M.S. Kwak, S. Kim, and J.S. Shin. 2014. The role of high mobility group box 1 in innate immunity. Yonsei Medical Journal 55: 1165–1176.CrossRefPubMedPubMedCentral Lee, S.A., M.S. Kwak, S. Kim, and J.S. Shin. 2014. The role of high mobility group box 1 in innate immunity. Yonsei Medical Journal 55: 1165–1176.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Qin, S., H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, et al. 2006. Role of HMGB1 in apoptosis-mediated sepsis lethality. The Journal of Experimental Medicine 203: 1637–1642.CrossRefPubMedPubMedCentral Qin, S., H. Wang, R. Yuan, H. Li, M. Ochani, K. Ochani, et al. 2006. Role of HMGB1 in apoptosis-mediated sepsis lethality. The Journal of Experimental Medicine 203: 1637–1642.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ueno, H., T. Matsuda, S. Hashimoto, F. Amaya, Y. Kitamura, M. Tanaka, et al. 2004. Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine 170: 1310–1316.CrossRefPubMed Ueno, H., T. Matsuda, S. Hashimoto, F. Amaya, Y. Kitamura, M. Tanaka, et al. 2004. Contributions of high mobility group box protein in experimental and clinical acute lung injury. American Journal of Respiratory and Critical Care Medicine 170: 1310–1316.CrossRefPubMed
14.
Zurück zum Zitat Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.CrossRefPubMedPubMedCentral Yang, H., M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Nosaka, N., M. Yashiro, M. Yamada, Y. Fujii, H. Tsukahara, K. Liu, et al. 2015. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Critical Care 19: 249.CrossRefPubMedPubMedCentral Nosaka, N., M. Yashiro, M. Yamada, Y. Fujii, H. Tsukahara, K. Liu, et al. 2015. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Critical Care 19: 249.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Yumoto, M., O. Nishida, K. Moriyama, Y. Shimomura, T. Nakamura, N. Kuriyama, et al. 2011. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Therapeutic Apheresis and Dialysis 15: 385–393.CrossRefPubMed Yumoto, M., O. Nishida, K. Moriyama, Y. Shimomura, T. Nakamura, N. Kuriyama, et al. 2011. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Therapeutic Apheresis and Dialysis 15: 385–393.CrossRefPubMed
17.
Zurück zum Zitat Honore, P.M., R. Jacobs, O. Joannes-Boyau, J. De Regt, E. De Waele, V. van Gorp, et al. 2013. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO Journal 59: 99–106.CrossRefPubMed Honore, P.M., R. Jacobs, O. Joannes-Boyau, J. De Regt, E. De Waele, V. van Gorp, et al. 2013. Newly designed CRRT membranes for sepsis and SIRS—a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review. ASAIO Journal 59: 99–106.CrossRefPubMed
18.
Zurück zum Zitat Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology 25: 280–288.CrossRefPubMed Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology 25: 280–288.CrossRefPubMed
19.
Zurück zum Zitat Liu, S.F., and A.B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L622–L645.CrossRefPubMed Liu, S.F., and A.B. Malik. 2006. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology 290: L622–L645.CrossRefPubMed
20.
Zurück zum Zitat Conti, L., S. Lanzardo, M. Arigoni, R. Antonazzo, E. Radaelli, D. Cantarella, et al. 2013. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB Journal 27: 4731–4744.CrossRefPubMed Conti, L., S. Lanzardo, M. Arigoni, R. Antonazzo, E. Radaelli, D. Cantarella, et al. 2013. The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB Journal 27: 4731–4744.CrossRefPubMed
Metadaten
Titel
Nobiletin: A Citrus Isolate to Make Sepsis Less Sour
verfasst von
Patrick M. Honore
Rita Jacobs
Inne Hendrickx
Elisabeth De Waele
Herbert D. Spapen
Publikationsdatum
20.02.2016
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2016
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0319-1

Weitere Artikel der Ausgabe 3/2016

Inflammation 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.